Lycotec Ltd, a biotech company based in Cambridge UK, is raising funds to undertake a phase II clinical trial which would target cholesterol crystals. These crystals are one of the main causes of the rupture of atherosclerotic plaques. After breaking the cap of a vulnerable plaque, the crystals protrude into the lumen of coronary or […]